On January 23, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, reported updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- to third-line disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

QUILT-3.078 enrolled patients with recurrent GBM at first recurrence. In the spIND population, seven patients were first line and are alive to date. Randomized clinical trials for both first line and second line+ GBM patients are in development.

QUILT-3.078 Phase 2 Results to Date

As of January 22, 2026, the study has enrolled 23 patients with recurrent or progressive GBM who progressed following standard-of-care therapy, including surgery, radiation, and temozolomide-based chemotherapy. 19 of the 23 enrolled patients remain alive, with four deaths reported to date.

Of the 23 enrolled patients, 14 currently have evaluable clinical data and comprise the efficacy population for the current analysis. Among these evaluable patients, a total of 139 doses of combination immunotherapy have been administered. The median follow up is 6 months in the evaluable cohort. All four deaths to date occurred within the evaluable cohort, and median overall survival has not yet been reached.

"Across contemporary studies, median overall survival for patients with recurrent glioblastoma is approximately six to nine months. Outcomes beyond this benchmark remain uncommon, underscoring the substantial unmet medical need in this disease. The patients enrolled in this study represent a particularly challenging population, having progressed after standard therapies and with severe lymphopenia. Observing ongoing treatment durability, survival beyond historical expectations in some patients, and a manageable safety profile without chemotherapy represents a paradigm change in the treatment of patients with glioblastoma," said Simon Khagi, M.D., MBA, Medical Director of Neuro Oncology at the Hoag Family Cancer Institute and Principal Investigator. Updated clinical findings will be presented by Dr. Simon Khagi at the Stand Up to Cancer Glioblastoma Innovation Scientific Summit on January 31, 2026 in Pasadena, Calif., including the focus on immune agonists as a combination backbone and the ImmunityBio Bioshield regimen.

Immune competence and lymphocyte recovery

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was approximately 900 cells per µL, consistent with lymphopenia commonly observed after prior therapy in recurrent GBM.

"These Phase 2 data reflect outcomes in a second- and third-line glioblastoma population where immune collapse after standard therapy is common and options are limited. With 19 of 23 enrolled patients alive and median overall survival not yet reached, the survival profile warrants continued follow up," said Patrick Soon Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "It has been extensively reported that patients with glioblastoma and lymphopenia have a significant decreased survival. Current standards of care, including radiation and chemotherapy (temozolomide), are potent drivers of lymphocyte depletion. The patients that entered this study all suffered profound lymphopenia, reflected by a baseline mean ALC of approximately 900, consistent with prior radiation and chemotherapy exposure. On treatment, we observed recovery and maintenance of lymphocyte counts without chemotherapy. Notably, within this broader clinical and compassionate use experience, we have also observed a near complete response with survival extending beyond twelve months from the time of documented disease progression, an outcome rarely seen in recurrent glioblastoma."

Safety

The treatment regimen has demonstrated a manageable safety profile. Three participants experienced serious adverse events suspected to be related to the experimental therapy. Importantly, no cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS) was observed.

"Glioblastoma remains one of the most lethal cancers we treat, with five-year survival still below ten percent and little meaningful improvement despite decades of drug development. A central challenge has been the disconnect between therapeutic development and a mechanistic understanding of how these agents behave in the human brain. Lymphopenia has been underrecognized as a significant consequence of our standards of care and the effect of a low ALC level on overall survival," said Joshua Bernstock, M.D., Ph.D., Clinical Fellow, Harvard Medical School and Neurosurgeon, Brigham and Women’s Hospital. "Approaches that integrate immune-based therapies that maintain immune competence with direct clinical and biological observation are essential if we are to make progress. Efforts that prioritize immune competence, durability of response, and data-driven evaluation represent an important step toward redefining how glioblastoma therapies are developed and assessed. I look forward to developing this new class of lymphocyte-stimulating agent and NK-based cellular therapy in glioblastoma with ImmunityBio."

About QUILT-3.078 (NCT06061809)

Overall survival is the primary endpoint of QUILT-3.078. The study includes an open-label, single-arm Phase 2 portion evaluating ANKTIVA (nogapendekin alfa inbakicept) in combination with PD-L1 t-haNK, bevacizumab, and Tumor Treating Fields in patients with recurrent glioblastoma.

The program also includes a randomized Phase 2B component designed to further evaluate durability of benefit. In Phase 2B, patients are randomized 1:1 to receive ANKTIVA, bevacizumab, and Tumor Treating Fields, either with or without PD-L1 t-haNK. Per protocol, study therapy is administered on an every-two-week dosing schedule within protocol-defined treatment periods. A Phase 2B expansion cohort is currently enrolling, with a target enrollment of 20 patients. To date, 8 patients have been enrolled in the Phase 2B cohort. This expansion is intended to further evaluate overall survival, durability of clinical outcomes, and exploratory immune biomarker analyses in this setting.

Single Patient IND (spIND) experience

In parallel with the clinical trial program, 18 patients with recurrent GBM have initiated treatment under a single patient IND, of which seven patients are first line.

About Glioblastoma

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Despite maximal multimodal therapy consisting of surgical resection, radiation, and temozolomide-based chemotherapy, outcomes remain poor. Median overall survival following initial diagnosis is approximately 14–16 months, and in the recurrent setting, median survival is typically ranges from 6 to 9 months. Five-year survival rates remain below 10 percent, underscoring the limited impact of existing therapeutic approaches.

A defining but underappreciated feature of glioblastoma management is treatment-induced immune suppression, particularly lymphopenia.[i], [ii] Multiple clinical studies have demonstrated that low absolute lymphocyte count (ALC) at baseline or following standard-of-care therapy is independently associated with inferior survival in glioblastoma[iii], regardless of tumor burden or extent of resection. Radiation[iv] and alkylating chemotherapy[v] have been shown to cause profound and durable depletion of circulating lymphocytes[vi], which may impair antitumor immune surveillance and limit the effectiveness of subsequent therapies.

Published analyses have further shown that persistent lymphopenia following chemoradiation is associated with shortened overall survival, while preservation or recovery of lymphocyte populations correlates with improved outcomes[vii]. These observations have contributed to growing recognition that immune competence is a biologically relevant determinant of survival in glioblastoma[viii], and that therapies capable of restoring or sustaining lymphocyte populations may be necessary to enable durable disease control. As a result, glioblastoma is increasingly understood not only as a locally aggressive malignancy, but also as a disease characterized by systemic immune collapse, creating a rationale for treatment strategies that prioritize immune restoration alongside tumor-directed interventions.

(Press release, ImmunityBio, JAN 23, 2026, View Source [SID1234662189])